title: Radiopharmaceuticals in positron emission tomography: present situation and future perspectives.
abstract: Positron emission tomography (PET) is an imaging technique that has grown greatly in recent years. PET is considered a fundamental tool in oncology, and it also has indications in other fields such as neurology and cardiology. Although18F-fluorodeoxyglucose (18F-FDG) is the radiopharmaceutical most widely used in PET, the availability of new radiotracers has been a key element in the expansion of the use of PET. These new radiopharmaceuticals have made it possible to study different biological targets that are essential for obtaining greater knowledge and better characterization of different diseases and have thus contributed to the research and development of different therapeutic agents. This article provides a description of different PET radiopharmaceutical, structured according to their areas of application. Some of these radiotracers are already commercially available, whereas others are still under research or pending approval by regulatory bodies.
authors: Unidad de Radiofarmacia, Servicio de Medicina Nuclear, Hospital Universitari i Politècnic La Fe, Valencia, España. Electronic address: olivas_con@gva.es.
authors: C
authors: C
authors: Olivas Arroyo
mesh_terms: D005544:Forecasting; D006331:Heart Diseases / Q000000981:diagnostic imaging; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging; D009422:Nervous System Diseases / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods* / Q000639:trends; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals
keywords: Cardiology; Cardiología; Neurology; Neurología; Oncology; Oncología; Positron emission tomography; Radiofármaco; Radiopharmaceutical; Tomografía por emisión de positrones